Jelena Klawitter
Concepts (535)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 15 | 2025 | 235 | 4.330 |
Why?
| | Metabolomics | 21 | 2025 | 733 | 2.880 |
Why?
| | Kidney | 21 | 2025 | 1496 | 2.580 |
Why?
| | Tandem Mass Spectrometry | 17 | 2026 | 572 | 2.560 |
Why?
| | Cardiopulmonary Bypass | 10 | 2025 | 219 | 2.120 |
Why?
| | Immunosuppressive Agents | 15 | 2019 | 838 | 1.770 |
Why?
| | Chromatography, High Pressure Liquid | 14 | 2024 | 592 | 1.730 |
Why?
| | Oxidative Stress | 18 | 2020 | 1359 | 1.600 |
Why?
| | Cyclosporine | 10 | 2019 | 256 | 1.590 |
Why?
| | Metabolome | 9 | 2025 | 391 | 1.280 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 440 | 1.180 |
Why?
| | Sirolimus | 9 | 2019 | 282 | 1.080 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.010 |
Why?
| | Kidney Transplantation | 11 | 2025 | 712 | 1.000 |
Why?
| | Cardiac Surgical Procedures | 3 | 2022 | 611 | 0.990 |
Why?
| | Biomarkers | 23 | 2025 | 4302 | 0.950 |
Why?
| | Pravastatin | 4 | 2025 | 45 | 0.890 |
Why?
| | Energy Metabolism | 8 | 2022 | 935 | 0.890 |
Why?
| | Proteomics | 14 | 2020 | 1188 | 0.880 |
Why?
| | Acute Kidney Injury | 3 | 2022 | 874 | 0.860 |
Why?
| | Allografts | 1 | 2025 | 152 | 0.850 |
Why?
| | Tryptophan | 5 | 2024 | 182 | 0.830 |
Why?
| | Tacrolimus | 5 | 2025 | 196 | 0.740 |
Why?
| | TRPP Cation Channels | 2 | 2024 | 74 | 0.730 |
Why?
| | Endocannabinoids | 4 | 2025 | 56 | 0.730 |
Why?
| | Kynurenine | 5 | 2024 | 114 | 0.730 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2025 | 444 | 0.710 |
Why?
| | Endothelium, Vascular | 5 | 2021 | 956 | 0.710 |
Why?
| | Lovastatin | 2 | 2013 | 37 | 0.700 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 560 | 0.680 |
Why?
| | Arginine | 2 | 2024 | 264 | 0.650 |
Why?
| | Menopause | 3 | 2020 | 326 | 0.650 |
Why?
| | Cannabinoids | 3 | 2024 | 184 | 0.640 |
Why?
| | Mass Spectrometry | 10 | 2021 | 731 | 0.620 |
Why?
| | Glomerular Filtration Rate | 11 | 2025 | 765 | 0.620 |
Why?
| | Heart Defects, Congenital | 5 | 2025 | 910 | 0.620 |
Why?
| | Myocardium | 2 | 2017 | 935 | 0.600 |
Why?
| | Kidney Failure, Chronic | 2 | 2025 | 599 | 0.600 |
Why?
| | Adenosine | 3 | 2018 | 255 | 0.570 |
Why?
| | Coronary Care Units | 1 | 2018 | 27 | 0.570 |
Why?
| | Signal Transduction | 11 | 2021 | 5223 | 0.570 |
Why?
| | Piperazines | 3 | 2009 | 375 | 0.560 |
Why?
| | Pyrimidines | 4 | 2014 | 530 | 0.530 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.520 |
Why?
| | Urine | 1 | 2017 | 64 | 0.510 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.510 |
Why?
| | Alkaline Phosphatase | 2 | 2018 | 144 | 0.490 |
Why?
| | Mycophenolic Acid | 3 | 2014 | 119 | 0.490 |
Why?
| | Male | 54 | 2026 | 73003 | 0.480 |
Why?
| | Length of Stay | 4 | 2025 | 1350 | 0.480 |
Why?
| | Chromatography, Liquid | 9 | 2026 | 450 | 0.470 |
Why?
| | Animals | 42 | 2024 | 38097 | 0.460 |
Why?
| | Plasma | 1 | 2017 | 223 | 0.460 |
Why?
| | Disease Models, Animal | 9 | 2024 | 4568 | 0.460 |
Why?
| | Adenosine Monophosphate | 1 | 2016 | 85 | 0.460 |
Why?
| | Female | 52 | 2026 | 79035 | 0.450 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 293 | 0.450 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.440 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 308 | 0.440 |
Why?
| | Humans | 75 | 2026 | 145763 | 0.440 |
Why?
| | Disease Progression | 8 | 2025 | 2865 | 0.430 |
Why?
| | Limit of Detection | 7 | 2024 | 92 | 0.420 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 7 | 0.410 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.410 |
Why?
| | Kidney Diseases | 4 | 2021 | 426 | 0.400 |
Why?
| | Dronabinol | 3 | 2026 | 249 | 0.400 |
Why?
| | Cell Proliferation | 4 | 2024 | 2514 | 0.400 |
Why?
| | Oxylipins | 2 | 2025 | 47 | 0.390 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 128 | 0.390 |
Why?
| | Inflammation | 9 | 2025 | 2883 | 0.380 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.380 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.370 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 71 | 0.370 |
Why?
| | Proteome | 3 | 2016 | 513 | 0.360 |
Why?
| | Oncogene Proteins | 1 | 2012 | 62 | 0.360 |
Why?
| | Dinoprost | 5 | 2019 | 51 | 0.360 |
Why?
| | Mutation | 2 | 2022 | 4090 | 0.350 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 849 | 0.350 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 264 | 0.340 |
Why?
| | Plant Extracts | 2 | 2024 | 188 | 0.340 |
Why?
| | Rats | 16 | 2024 | 5585 | 0.340 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 165 | 0.340 |
Why?
| | Nitric Oxide | 4 | 2024 | 892 | 0.330 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 285 | 0.320 |
Why?
| | Mitochondria | 1 | 2017 | 992 | 0.320 |
Why?
| | Purines | 2 | 2022 | 187 | 0.320 |
Why?
| | Postoperative Complications | 3 | 2021 | 2977 | 0.320 |
Why?
| | Blotting, Western | 6 | 2012 | 1184 | 0.310 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 627 | 0.310 |
Why?
| | Hypoxia | 6 | 2024 | 1199 | 0.300 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 457 | 0.300 |
Why?
| | Mice, Inbred C57BL | 12 | 2023 | 5992 | 0.290 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 356 | 0.290 |
Why?
| | Prostaglandins | 3 | 2022 | 94 | 0.290 |
Why?
| | Ureteral Obstruction | 2 | 2021 | 63 | 0.290 |
Why?
| | Theophylline | 2 | 2020 | 41 | 0.290 |
Why?
| | Autophagy | 3 | 2024 | 291 | 0.290 |
Why?
| | Glycolysis | 4 | 2012 | 340 | 0.280 |
Why?
| | Mice | 19 | 2024 | 18355 | 0.280 |
Why?
| | Infant | 10 | 2025 | 10090 | 0.280 |
Why?
| | Antineoplastic Agents | 3 | 2009 | 2219 | 0.280 |
Why?
| | Arachidonate 12-Lipoxygenase | 2 | 2021 | 17 | 0.280 |
Why?
| | Arachidonate 15-Lipoxygenase | 2 | 2021 | 20 | 0.280 |
Why?
| | Mice, Knockout | 7 | 2023 | 3130 | 0.270 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3551 | 0.260 |
Why?
| | Vascular Diseases | 2 | 2021 | 252 | 0.260 |
Why?
| | Case-Control Studies | 7 | 2024 | 3634 | 0.260 |
Why?
| | Amino Acids | 2 | 2025 | 519 | 0.260 |
Why?
| | Blood Vessels | 2 | 2019 | 167 | 0.260 |
Why?
| | Prospective Studies | 13 | 2025 | 8075 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2009 | 883 | 0.250 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3416 | 0.250 |
Why?
| | Time Factors | 8 | 2022 | 7133 | 0.240 |
Why?
| | Infant, Newborn | 8 | 2025 | 6464 | 0.240 |
Why?
| | Rats, Wistar | 6 | 2018 | 450 | 0.240 |
Why?
| | Microsomes, Liver | 2 | 2019 | 85 | 0.230 |
Why?
| | Deoxyglucose | 2 | 2024 | 51 | 0.230 |
Why?
| | Child | 10 | 2025 | 22739 | 0.220 |
Why?
| | Swine | 3 | 2022 | 826 | 0.220 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 73 | 0.220 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.220 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2393 | 0.220 |
Why?
| | Alkaloids | 1 | 2024 | 28 | 0.220 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 68 | 0.220 |
Why?
| | Treatment Outcome | 9 | 2025 | 11793 | 0.210 |
Why?
| | Mitragyna | 1 | 2024 | 8 | 0.210 |
Why?
| | Young Adult | 12 | 2023 | 14251 | 0.210 |
Why?
| | Adult | 19 | 2026 | 40872 | 0.210 |
Why?
| | Transplantation, Homologous | 1 | 2025 | 419 | 0.210 |
Why?
| | Adolescent | 10 | 2025 | 22573 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 16 | 0.200 |
Why?
| | Arachidonic Acids | 1 | 2024 | 42 | 0.200 |
Why?
| | Citrulline | 1 | 2024 | 45 | 0.200 |
Why?
| | Graft Rejection | 4 | 2017 | 521 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 41 | 0.190 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 26 | 0.190 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2012 | 110 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 106 | 0.190 |
Why?
| | Cytokines | 5 | 2025 | 2069 | 0.190 |
Why?
| | Tissue Distribution | 2 | 2014 | 335 | 0.180 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 28 | 0.180 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 593 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2021 | 507 | 0.170 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 115 | 0.170 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.170 |
Why?
| | Aminophylline | 2 | 2020 | 12 | 0.170 |
Why?
| | Double-Blind Method | 6 | 2025 | 2064 | 0.170 |
Why?
| | Curcumin | 1 | 2021 | 29 | 0.170 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 302 | 0.170 |
Why?
| | Fetal Diseases | 1 | 2023 | 194 | 0.170 |
Why?
| | Middle Aged | 17 | 2025 | 36302 | 0.170 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 77 | 0.170 |
Why?
| | Indoles | 1 | 2025 | 507 | 0.170 |
Why?
| | Vascular Stiffness | 3 | 2021 | 487 | 0.170 |
Why?
| | Calcium Channels, T-Type | 1 | 2022 | 104 | 0.160 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.160 |
Why?
| | Hypothalamus | 2 | 2018 | 163 | 0.160 |
Why?
| | Databases, Genetic | 1 | 2022 | 238 | 0.160 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 121 | 0.160 |
Why?
| | Methionine | 1 | 2021 | 161 | 0.160 |
Why?
| | Organ Size | 2 | 2025 | 461 | 0.160 |
Why?
| | Niacinamide | 1 | 2021 | 104 | 0.160 |
Why?
| | Benzamides | 3 | 2009 | 226 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 399 | 0.150 |
Why?
| | Nephrectomy | 1 | 2021 | 163 | 0.150 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2020 | 50 | 0.150 |
Why?
| | Vasodilation | 3 | 2018 | 521 | 0.150 |
Why?
| | Cannabidiol | 1 | 2022 | 142 | 0.150 |
Why?
| | Pain | 1 | 2025 | 791 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 18 | 0.150 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 96 | 0.150 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 69 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 85 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 28 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 307 | 0.140 |
Why?
| | Spironolactone | 1 | 2019 | 40 | 0.140 |
Why?
| | Vitamin D | 2 | 2019 | 404 | 0.140 |
Why?
| | Blood Proteins | 1 | 2020 | 239 | 0.140 |
Why?
| | Homocysteine | 1 | 2019 | 152 | 0.140 |
Why?
| | Glucose | 2 | 2017 | 1048 | 0.140 |
Why?
| | Brain | 2 | 2013 | 2969 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 334 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2020 | 192 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 69 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 437 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 265 | 0.130 |
Why?
| | Phenotype | 3 | 2022 | 3170 | 0.130 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 46 | 0.130 |
Why?
| | 5'-Nucleotidase | 1 | 2018 | 49 | 0.130 |
Why?
| | Therapies, Investigational | 1 | 2017 | 19 | 0.130 |
Why?
| | Phenylpropionates | 1 | 2017 | 27 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 329 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 211 | 0.130 |
Why?
| | Complement Factor B | 1 | 2018 | 106 | 0.130 |
Why?
| | Terbutaline | 1 | 2017 | 7 | 0.130 |
Why?
| | Endothelins | 1 | 2017 | 61 | 0.130 |
Why?
| | Sex Characteristics | 2 | 2013 | 789 | 0.130 |
Why?
| | Cell Cycle | 2 | 2011 | 598 | 0.130 |
Why?
| | Pyridazines | 1 | 2017 | 57 | 0.130 |
Why?
| | Protein Kinases | 2 | 2017 | 312 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 125 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 90 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 136 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 79 | 0.130 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2018 | 194 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 768 | 0.120 |
Why?
| | Receptors, Calcitriol | 1 | 2017 | 56 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 172 | 0.120 |
Why?
| | Immunoglobulin M | 1 | 2018 | 265 | 0.120 |
Why?
| | Glutamic Acid | 1 | 2018 | 255 | 0.120 |
Why?
| | Brachial Artery | 4 | 2019 | 208 | 0.120 |
Why?
| | Calcineurin Inhibitors | 2 | 2014 | 69 | 0.120 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.120 |
Why?
| | Drug Synergism | 2 | 2014 | 354 | 0.120 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.120 |
Why?
| | Breast | 1 | 2017 | 156 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2013 | 88 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1180 | 0.120 |
Why?
| | Helminth Proteins | 1 | 2016 | 24 | 0.120 |
Why?
| | Extracellular Space | 1 | 2016 | 117 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 240 | 0.120 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 5 | 0.110 |
Why?
| | Transplant Recipients | 1 | 2017 | 182 | 0.110 |
Why?
| | Linoleic Acids | 1 | 2015 | 6 | 0.110 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 35 | 0.110 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.110 |
Why?
| | Enzyme Activation | 1 | 2017 | 762 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2123 | 0.110 |
Why?
| | Therapeutic Equivalency | 2 | 2017 | 31 | 0.110 |
Why?
| | Fishes | 1 | 2016 | 110 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 145 | 0.110 |
Why?
| | Premature Birth | 1 | 2019 | 390 | 0.110 |
Why?
| | Postoperative Period | 1 | 2016 | 351 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 528 | 0.110 |
Why?
| | Reperfusion Injury | 1 | 2018 | 292 | 0.110 |
Why?
| | Diet, Sodium-Restricted | 1 | 2015 | 38 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2019 | 440 | 0.110 |
Why?
| | Biological Availability | 2 | 2017 | 145 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 638 | 0.110 |
Why?
| | Serine | 1 | 2015 | 143 | 0.100 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 169 | 0.100 |
Why?
| | Macrophages, Alveolar | 2 | 2016 | 373 | 0.100 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 452 | 0.100 |
Why?
| | DNA Methylation | 1 | 2019 | 690 | 0.100 |
Why?
| | Tidal Volume | 1 | 2014 | 109 | 0.100 |
Why?
| | Child, Preschool | 3 | 2025 | 11868 | 0.100 |
Why?
| | Cannabis | 1 | 2021 | 510 | 0.100 |
Why?
| | Hospital Mortality | 1 | 2018 | 1038 | 0.100 |
Why?
| | Cattle | 1 | 2016 | 946 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 21 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 303 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1300 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 337 | 0.100 |
Why?
| | Everolimus | 2 | 2012 | 112 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1973 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 107 | 0.100 |
Why?
| | Respiration, Artificial | 2 | 2018 | 714 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2110 | 0.100 |
Why?
| | Reactive Oxygen Species | 3 | 2012 | 611 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 382 | 0.100 |
Why?
| | Lung | 3 | 2022 | 4116 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2399 | 0.090 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 59 | 0.090 |
Why?
| | Cytoprotection | 1 | 2012 | 56 | 0.090 |
Why?
| | Pilot Projects | 4 | 2023 | 1897 | 0.090 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 15 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 73 | 0.090 |
Why?
| | Ion Transport | 1 | 2012 | 62 | 0.090 |
Why?
| | K562 Cells | 2 | 2009 | 92 | 0.090 |
Why?
| | Gluconeogenesis | 1 | 2012 | 81 | 0.090 |
Why?
| | Nicorandil | 1 | 2012 | 11 | 0.090 |
Why?
| | Glutamine | 1 | 2012 | 109 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 90 | 0.090 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 19 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 136 | 0.090 |
Why?
| | Regression Analysis | 2 | 2012 | 1001 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2933 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5922 | 0.090 |
Why?
| | Androgens | 1 | 2013 | 181 | 0.090 |
Why?
| | Phosphates | 1 | 2012 | 177 | 0.090 |
Why?
| | Glucuronides | 1 | 2011 | 18 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2018 | 877 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 668 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Administration, Oral | 3 | 2026 | 867 | 0.080 |
Why?
| | Cytoskeleton | 1 | 2012 | 192 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3346 | 0.080 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 203 | 0.080 |
Why?
| | Lung Injury | 1 | 2014 | 249 | 0.080 |
Why?
| | Fatty Acids | 1 | 2014 | 457 | 0.080 |
Why?
| | Models, Animal | 1 | 2013 | 392 | 0.080 |
Why?
| | Aged | 7 | 2025 | 26215 | 0.080 |
Why?
| | Artifacts | 1 | 2011 | 143 | 0.080 |
Why?
| | Cell Survival | 2 | 2012 | 1103 | 0.080 |
Why?
| | Serotonin | 2 | 2024 | 298 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2017 | 826 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 58 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 367 | 0.080 |
Why?
| | Drugs, Generic | 1 | 2010 | 28 | 0.080 |
Why?
| | Cross Reactions | 1 | 2010 | 130 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2014 | 1165 | 0.080 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2007 | 174 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 104 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2013 | 359 | 0.070 |
Why?
| | Drug Approval | 1 | 2010 | 93 | 0.070 |
Why?
| | Reference Standards | 1 | 2009 | 177 | 0.070 |
Why?
| | Heart Ventricles | 2 | 2024 | 756 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2013 | 4151 | 0.070 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 48 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 118 | 0.070 |
Why?
| | Risk Assessment | 1 | 2018 | 3752 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1777 | 0.070 |
Why?
| | Lysosomes | 2 | 2021 | 131 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 2000 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 550 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1708 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2012 | 322 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2017 | 610 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Astrocytes | 1 | 2010 | 228 | 0.070 |
Why?
| | Phospholipids | 1 | 2009 | 214 | 0.070 |
Why?
| | Lactic Acid | 1 | 2009 | 295 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 164 | 0.070 |
Why?
| | Apoptosis | 3 | 2012 | 2443 | 0.070 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 21 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 529 | 0.060 |
Why?
| | Fibrosis | 2 | 2021 | 561 | 0.060 |
Why?
| | Allergens | 1 | 2010 | 386 | 0.060 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 675 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 174 | 0.060 |
Why?
| | Nucleotides | 1 | 2007 | 129 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 47 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1276 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1134 | 0.060 |
Why?
| | Estradiol | 2 | 2020 | 515 | 0.060 |
Why?
| | Pulse Wave Analysis | 2 | 2018 | 267 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 435 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2205 | 0.060 |
Why?
| | Renal Circulation | 1 | 2025 | 75 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2024 | 456 | 0.050 |
Why?
| | Kynurenic Acid | 1 | 2024 | 18 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1797 | 0.050 |
Why?
| | Isomerism | 1 | 2024 | 56 | 0.050 |
Why?
| | Blood Pressure | 3 | 2019 | 1782 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1969 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2008 | 401 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10917 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 33 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3195 | 0.050 |
Why?
| | Palliative Care | 2 | 2024 | 1022 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1271 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 90 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2025 | 251 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 131 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3118 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 322 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 2 | 2013 | 53 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 33 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.050 |
Why?
| | Androstanols | 1 | 2022 | 30 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1043 | 0.050 |
Why?
| | Urinalysis | 2 | 2015 | 83 | 0.040 |
Why?
| | Drug Interactions | 2 | 2017 | 405 | 0.040 |
Why?
| | Steroids | 1 | 2022 | 160 | 0.040 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 34 | 0.040 |
Why?
| | Cell Line | 2 | 2021 | 2823 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 137 | 0.040 |
Why?
| | Nitriles | 1 | 2022 | 211 | 0.040 |
Why?
| | Pregnancy | 3 | 2019 | 7215 | 0.040 |
Why?
| | Rats, Inbred Lew | 2 | 2012 | 105 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 93 | 0.040 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 73 | 0.040 |
Why?
| | Drug Stability | 2 | 2011 | 169 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 89 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 62 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 161 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2020 | 33 | 0.040 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2020 | 25 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2022 | 222 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 6032 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 148 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 138 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 149 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 296 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1261 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.040 |
Why?
| | Molecular Structure | 2 | 2014 | 487 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 82 | 0.040 |
Why?
| | Pulmonary Veins | 1 | 2020 | 108 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1278 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 93 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 162 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 175 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Reference Values | 2 | 2013 | 798 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 515 | 0.030 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 38 | 0.030 |
Why?
| | Complement C5a | 1 | 2018 | 54 | 0.030 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2018 | 25 | 0.030 |
Why?
| | Rewarming | 1 | 2018 | 21 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 81 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2191 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 190 | 0.030 |
Why?
| | Position-Specific Scoring Matrices | 1 | 2017 | 2 | 0.030 |
Why?
| | Birth Weight | 1 | 2020 | 517 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2018 | 208 | 0.030 |
Why?
| | Femoral Artery | 1 | 2018 | 190 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1751 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 155 | 0.030 |
Why?
| | Malates | 1 | 2016 | 8 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 318 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1115 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 394 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 559 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 316 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1068 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 219 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 143 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 67 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 353 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 36 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2028 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 473 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 620 | 0.030 |
Why?
| | Aldehydes | 1 | 2016 | 140 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 692 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 396 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 57 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 314 | 0.030 |
Why?
| | Safety | 1 | 2017 | 358 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 981 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 242 | 0.030 |
Why?
| | Larva | 1 | 2016 | 240 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 21 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 31 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 381 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 571 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1568 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 88 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2017 | 896 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 318 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 66 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1547 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 58 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Prognosis | 2 | 2013 | 4329 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 96 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 14 | 0.030 |
Why?
| | Macrophages | 1 | 2021 | 1507 | 0.030 |
Why?
| | Binding Sites | 1 | 2017 | 1311 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 112 | 0.020 |
Why?
| | Thiazoles | 1 | 2014 | 142 | 0.020 |
Why?
| | Dihydrotestosterone | 1 | 2013 | 40 | 0.020 |
Why?
| | Altitude | 1 | 2017 | 463 | 0.020 |
Why?
| | Orchiectomy | 1 | 2013 | 72 | 0.020 |
Why?
| | Cell Count | 1 | 2013 | 319 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2015 | 514 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 53 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 41 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 172 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 693 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 187 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 75 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 337 | 0.020 |
Why?
| | Streptozocin | 1 | 2012 | 22 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2013 | 149 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 194 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 172 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1812 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1118 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 242 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 202 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 147 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 614 | 0.020 |
Why?
| | Transplantation | 1 | 2011 | 33 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 578 | 0.020 |
Why?
| | Podocytes | 1 | 2012 | 80 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 88 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1450 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 242 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 716 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2240 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 289 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 199 | 0.020 |
Why?
| | Daucus carota | 1 | 2010 | 2 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 655 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 638 | 0.020 |
Why?
| | Buffers | 1 | 2010 | 56 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2010 | 24 | 0.020 |
Why?
| | Graft Survival | 1 | 2012 | 519 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 858 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 403 | 0.020 |
Why?
| | Hot Temperature | 1 | 2012 | 396 | 0.020 |
Why?
| | Antigens, Plant | 1 | 2010 | 55 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1764 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 177 | 0.020 |
Why?
| | Ribose | 1 | 2009 | 22 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 387 | 0.020 |
Why?
| | Plant Proteins | 1 | 2010 | 111 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2447 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1378 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 376 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 9 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 821 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 83 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 125 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 208 | 0.020 |
Why?
| | Vegetables | 1 | 2010 | 162 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 17325 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2009 | 143 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2525 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 910 | 0.020 |
Why?
| | Liver | 1 | 2016 | 1899 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 442 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 346 | 0.020 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 979 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2131 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1857 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2883 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2967 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4556 | 0.010 |
Why?
| | Neurons | 1 | 2013 | 1652 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 422 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2601 | 0.010 |
Why?
| | United States | 1 | 2010 | 16123 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|